Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 3,754 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Active, not recruiting Phase 1 Interventional Results available

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT02537613
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Obinutuzumab, Ibrutinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

NCT02416908
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Selinexor, Cladribine, G-CSF, Cytarabine, Bone marrow biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

NCT01453491
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults

NCT04871113
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3810109A, Dolutegravir+lamivudine SOC regimen
Biological
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 4 Interventional Results available

Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures

NCT03385304
View directory record Official record
Conditions
Surgical Site Infection, Unplanned Fracture-Related Reoperation, Open Appendicular Fracture
Interventions
10% povidone-iodine (1% free iodine) in purified water, 4% chlorhexidine gluconate (CHG) in purified water
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
1,638 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 30, 2026, 11:57 PM EDT
Recruiting Phase 2 Interventional

Cabozantinib for Patients With Recurrent or Progressive Meningioma

NCT05425004
View directory record Official record
Conditions
Meningioma
Interventions
Cabozantinib
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Brain on Whole Body Hyperthermia: A Neuroimaging Study

NCT02062840
View directory record Official record
Conditions
Major Depression
Interventions
High intensity whole-body infrared heating, Low intensity whole-body infrared heating, Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG), Questionnaires
Device · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma

NCT00065468
View directory record Official record
Conditions
Carcinoma, Renal Cell, Kidney Neoplasms
Interventions
Interferon Alfa, CCI-779, Interferon Alfa and CCI-779
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
48
States / cities
Little Rock, Arkansas • La Verne, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 30, 2026, 11:57 PM EDT
Terminated Phase 2 Interventional Results available

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT01186406
View directory record Official record
Conditions
Glioblastoma Multiforme, Gliosarcoma
Interventions
Gliadel, Radiation Therapy, Avastin, Temodar
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Not applicable Interventional Results available

Orthostatic Hypotension in Rehabilitation Patients

NCT00117585
View directory record Official record
Conditions
Hypotension, Orthostatic
Interventions
Treatment Phase 1, Treatment Phase 2, Treatment Phase 3
Other · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 30, 2026, 11:57 PM EDT
Not listed No phase listed Observational

Behavioral and Environmental Sensing and Intervention

NCT03297268
View directory record Official record
Conditions
Behavioral and Psychiatric Symptoms of Dementia, Dementia, Caregivers
Interventions
Intervention with Home-Based Caregivers
Other
Lead sponsor
University of Virginia
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 30, 2026, 11:57 PM EDT
Terminated Phase 4 Interventional Results available

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT04507204
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Adhansia XR, Concerta
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
12 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
35
States / cities
Dothan, Alabama • Beverly Hills, California • Cromwell, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 2 Interventional

Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures

NCT00384358
View directory record Official record
Conditions
Fractures
Interventions
rhBMP-2/CPM, surgical intervention alone
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
55 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
8
States / cities
Aurora, Colorado • New Haven, Connecticut • Clearwater, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 2 Interventional

Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

NCT00024154
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
trastuzumab, gefitinib, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 30, 2026, 11:57 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Sonication-based OCD Neurosurgical Intervention Via Capsulotomy

NCT06131502
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Palo Alto, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 1 Interventional

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

NCT03810807
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Dacomitinib, Osimertinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

NCT00671671
View directory record Official record
Conditions
Hepatitis, Chronic, Hepatitis C Virus
Interventions
Small Molecule Agent (PF-868554)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 30, 2026, 11:57 PM EDT
Not yet recruiting Phase 2 Interventional

A Clinical Study of Ixazomib to Reactivate HIV and Reduce HIV Reservoir Size

NCT07881809
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
Ixazomib 4 mg, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

NCT01642186
View directory record Official record
Conditions
Fibrolamellar Carcinoma, Fibrolamellar Liver Cancer
Interventions
everolimus, letrozole plus leuprolide, combination of everolimus, letrozole and leuprolide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 1 Interventional

Dose-Escalation Study of GSK2126458

NCT00972686
View directory record Official record
Conditions
Solid Tumours
Interventions
GSK2126458
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
7
States / cities
San Francisco, California • New Brunswick, New Jersey • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 30, 2026, 11:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

NCT02018861
View directory record Official record
Conditions
B-Cell Malignancies
Interventions
Parsaclisib, Itacitinib, Rituximab, Ifosfamide, Carboplatin, Etoposide
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 30, 2026, 11:57 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

NCT04673942
View directory record Official record
Conditions
Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
Interventions
AdAPT-001, Checkpoint Inhibitor, Immune
Biological · Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Duarte, California • San Marcos, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 11:57 PM EDT